Joana Fernandes, PhD,  —

Blood levels of a protein called sCD40L may serve as a biomarker to track lung complications in patients with cystic fibrosis (CF) infected by Pseudomonas aeruginosa bacteria, according to a new study. Results of the study were reported in the article “A High Level Of Soluble CD40L Is Associated With P. aeruginosa…

Mortality rates among cystic fibrosis (CF) patients in the United States have significantly decreased during the past decade, but hospitalizations and in-hospital deaths seem to be on the rise, according to the results of a new study. “Contemporary National Trends Of Cystic Fibrosis Hospitalizations And Co-Morbidities In The United States” was…

A recent study reported experiences and perceptions among parents whose children have been diagnosed with cystic fibrosis (CF) or sickle cell disease (SCD) via the newborn screening (NBS) program in the United Kingdom. Not surprisingly, the results showed that a positive NBS result may have a profound psychosocial impact on parents,…

A Phase 1 clinical trial will evaluate the safety and tolerability of GLPG2737 as a possible treatment for cystic fibrosis (CF), Galapagos NV announced. CF is caused by mutations in the CFTR gene, which encodes a protein channel with the same name. When mutated, this protein can no longer transport chloride…

Several factors may worsen lung infections caused by the bacteria Staphylococcus aureus in cystic fibrosis (CF) patients, from bacterial load to co-infections, according to a new study. The study, “Factors Associated With Worse Lung Function In Cystic Fibrosis Patients With Persistent Staphylococcus aureus,” was published in the journal PLoS One.

People interested in knowing more about gene editing and its therapeutic applications can now download a document prepared by the American Society of Gene & Cell Therapy (ASGCT). The document, titled “Therapeutic Gene Editing: An ASGCT White Paper,” is intended as background information for policymakers, patients, and the general public…

Researchers have found that a “swimming”  movement by Pseudomonas aeruginosa, the bacteria most commonly associated with lung infections in cystic fibrosis (CF) patients, triggers an immune response against the pathogen, according to a new study. Its findings may help in targeting therapies to resolve lung infection in CF. The study, “Swimming Motility Mediates…

Children diagnosed with cystic fibrosis (CF) months after their birth have worse clinical outcomes than those diagnosed as newborns, a study reports. Its authors argue for improvements in CF diagnostic programs to detect these cases in infants as early as possible. The study, “Differences In Outcomes Between Early And Late Diagnosis Of Cystic Fibrosis…

Children with cystic fibrosis (CF) who carry the F508del mutation in both CFTR gene copies showed improved lung function after treatment with Orkambi (ivacaftor/lumacaftor), according to results in a Phase 3 study developed by Vertex Pharmaceuticals. The study, in pediatric patients ages 6–11, evaluated the effect of Orkambi…

Alcresta Therapeutics announced that its product RELiZORB effectively increased fat absorption in cystic fibrosis (CF) patients receiving enteral tube feeding and who have trouble breaking down and absorbing these molecules, resulting in reduced frequency and severity of gastrointestinal symptoms among those patients. The findings were presented at the 30th…